Under the direction of Drs. Shelton Earp, Charles Perou, and Lisa Carey, SPORE PI and Co-PIs, the Administration Core supports the UNC Breast Cancer SPORE's overall scientific/ translational goals by providing leadership and, with the help of superb staff, day-to-day administration. The Core organizes intra and inter-SPORE interactions;administrative/scientific oversight of all research projects, cores, and developmental programs;interaction with NCI and the SPORE program;and planning and evaluation activities. This Core also monitors SPORE expenditures and addresses grant management issues. Like the SPORE itself, the Administration Core blends experienced and stable leadership with new expertise, energy, and perspective. Because the SPORE PI Dr. Earp is also Cancer Center Director, this Administration Core links the Breast SPORE to the UNC Lineberger Comprehensive Cancer Center and its other large translational efforts (e.g. DoD Prostate Cancer Center of Excellence, Center of Cancer Nanotechnology Excellence, the Cancer Genome Atlas), as well as to the University, School of Medicine, and Hospital administration.
The Administration Core supports the five projects and core resources that will continue to explore the effect of intrinsic subtype on the predisposition, progression, and therapeutic resistance of difficult-to-treat breast cancers.
|Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987|
|Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:|
|Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829|
|Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383|
|Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39|
|Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820|
|Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701|
|Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330|
|Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86|
|Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304|
Showing the most recent 10 out of 598 publications